Navigating Multiple Myeloma: From Newly Diagnosed to R/R
Rafael Fonseca, MD; Binod Dhakal, MD; Doris K. Hansen, MD; and Adriana Rossi, MD, explore evidence-based treatment strategies for newly diagnosed patients, focusing on transplant-ineligible cases, current therapeutic guidelines, and emerging clinical trial data such as the CEPHEUS study comparing daratumumab plus VRd vs VRd alone.
EP. 1: Expert Insights: Navigating the Evolving Treatment Landscape in NDMM
December 18th 2024Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, are reshaping the standard of care for patients with newly diagnosed multiple myeloma (NDMM) while emphasizing the importance of risk stratification and early intervention strategies.
Watch
Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on patient characteristics, efficacy data, and safety profiles to achieve optimal outcomes.
Watch
Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma, highlighting key outcomes and clinical implications.
Watch
